Intranasal drug delivery for treatment of Alzheimer's disease
- PMID: 33638130
- DOI: 10.1007/s13346-021-00940-7
Intranasal drug delivery for treatment of Alzheimer's disease
Abstract
The Alzheimer's disease is a neurodegenerative condition with severe consequences interfering with patient quality of life. It is characterized as a progressive and irreversible brain disorder hampering memory and thinking, affecting the capacity to perform daily tasks leading to physical and cognitive incapacitation. The conventional treatment occurs by the oral route, but it presents relevant drawbacks such as low bioavailability, fast metabolism, limited brain exposure, and undesirable side effects. The intranasal route has been proposed as a promising alternative to deliver drugs and improve the Alzheimer's disease treatment. Still, there is not a clear alternative delivery system available in the market with advantageous bioavailability and safety. The aim of this review is to perform an overview on the strategies for drug intranasal delivery for Alzheimer's disease treatment. The advantages and disadvantages of this delivery route and the delivery systems developed so far are discussed. A special focus is given on the use of permeation enhancers, the types of intranasal drug delivery devices, as well as possible toxicity concerns.
Keywords: Blood-brain barrier; Central nervous system; Nanoparticle; Neurodegenerative; Permeation enhancer; Protein.
References
-
- Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep. 2016;3391–6.
-
- Chapman CD, Frey WH, Craft S, Danielyan L, Hallschmid M, Schiöth HB, et al. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res. 2013;30:2475–84. - PubMed
-
- Thies W, Bleiler L. Alzheimer’s disease facts and figures. Alzheimer’s Dement J Elsevier Ltd. 2013;9:208–45.
-
- Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88–106.
-
- Dufes C, Olivier J, Gaillard F, Gaillard A, Couet W, Muller J. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm. 2003;255:87–97. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
